Back to Journals » OncoTargets and Therapy » Volume 10

Expression of SHP-1 and SOCS6 in patients with acute leukemia and their clinical implication

Authors Liu J, Zheng Y, Gao J, Zhu G, Gao K, Zhang W, Shi F, Shi Q

Received 3 January 2017

Accepted for publication 1 March 2017

Published 29 March 2017 Volume 2017:10 Pages 1915—1920

DOI https://doi.org/10.2147/OTT.S131537

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 2

Editor who approved publication: Dr Samir Farghaly

Jinmei Liu,1 Yurong Zheng,1 Ju Gao,1 Guimei Zhu,1 Kun Gao,2 Wenzhen Zhang,3 Fangyan Shi,4 Qing Zhang5

1Department of Hematology, Kailuan General Hospital, 2Department of Emergency, Tangshan Union Medical College Hospital, 3Department of Clinical Laboratory, Tangshan People’s Hospital, 4Department of Blood Dialysis, Linxi Hospital, 5Department of Ultrasonography, Tangshan, People’s Republic of China

Background: To investigate the expression and clinical relevance of Src homology region 2 domain-containing phosphatase-1 (SHP-1) and suppressor of cytokine signaling 6 (SOCS6) in acute leukemia (AL).
Patients and methods: The enrolled AL patients were divided into three groups (newly diagnosed, relapsed, and complete remission [CR]). Healthy donors were also included as a control group in this study. Semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) was performed to measure messenger RNA (mRNA) expression of SHP-1 and SOCS6. Statistical analysis was conducted to analyze the correlation between mRNA levels of SHP-1 and SOCS6 with patient outcomes.
Results: mRNA expression of SHP-1 was significantly lower in AL patients than that in healthy donors. The newly diagnosed or relapsed AL patients had lower mRNA levels of SHP-1 than the patients in CR. In contrast, SOCS6 mRNA expression was significantly higher in newly diagnosed or relapsed patients than that in patients in CR as well as healthy donors. However, mRNA levels of both SHP-1 and SOCS6 were positively correlated with the patient remission. The chemotherapy-induced remission rate was higher in patients with detectable SHP-1 or SOCS6 expression than in patients with undetectable SHP-1 or SOCS6 expression. Furthermore, the AL patients with detectable SHP-1 mRNA expression had lower incidence rate of invasive fungal infection.
Conclusion: The results suggest that expression patterns of SHP-1 and SOCS6 differ in AL patients. Despite the difference, expression of SHP-1 and SOCS6 is associated with favorable outcomes, suggesting an anticancer property of these two genes in AL.

Keywords: SHP-1, SOCS6, leukemia, prognosis, invasive fungal infection

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]